Advertisement

Highlights of Abstracts on Plasma Cell Dyscrasia in the Annual Conference ISHBT (Kochi)

  • Tathagat ChatterjeeEmail author
  • Ankur Ahuja
Short Communication
  • 6 Downloads

Abstract

Since last few years plasma cell dyscrasias have been in the hit list of research especially pertaining to its therapy and pathophysiology. India has taken a great leap as far as research in plasma cell dyscrasias is concerned. The year started with myeloma conference in New Delhi conducted by Army Hospital (R&R) and ended at Haematocon Kochi organised by team from CMC Vellore (Haematocon 2018). Haematocon 2018 provided an exceptional platform for the research on various aspects of plasma cell dyscrasias both from the country and abroad. A total of 23 abstracts were presented pertaining to plasma cell disorders; 13 original research papers, 08 case reports and 02 case series. There were a wide spectrum of papers which ranged from the discussion about morphological aspects, mimickers, clinical spectrum, life style in the setting of the disease, diagnostic modalities to management aspects and finally to progress and survival of these patients. Through this review we will summarize and analyze the key findings of the original research abstracts on diagnosis, risk stratification, clinical profile and treatment aspects of plasma cell disorders presented at the Haematocon 2018.

Keywords

FISH in myeloma Cytogenetics in myeloma Cryopreserved grafts Quality of life in myeloma patients Myeloma chemotherapy Refractory myeloma 

Notes

Acknowledgements

We acknowledge the support of ISHBT, as with their support the study had been feasible.

Authors’ Contributions

TC and AA were involved in conceptualization, designing, writing and critical review of the manuscript, in literature search, writing and manuscript editing and were responsible for overall supervision.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Shruthi V, Manipadam MT, Geevar T (2018) Looks can be deceptive-anaplastic myeloma mimicking myelodysplastic syndrome (Haematocon 2018-257). Indian J Hematol Blood Transfus 34(issue 1 supplement):365Google Scholar
  2. 2.
    Agarwal A, Singh A, Tanweer N (2018) Plasma cell leukemia with plasmablastic morphology mimicking acute myeloid leukaemia—a rare case report (Haematocon 2018-420). Indian J Hematol Blood Transfus 34(issue 1 supplement):262Google Scholar
  3. 3.
    Monica S, Khan EM, Basu A (2018) A case of multiple myeloma with plasmablastic morphology—a rare variant (Haematocon 2018-228). Indian J Hematol Blood Transfus 34(issue 1 supplement):362Google Scholar
  4. 4.
    Venkatesan S, Sharma S (2018) Unusual morphological variants of plasma cell neoplasms (Haematocon 2018-294). Indian J Hematol Blood Transfus (issue 1 supplement):366Google Scholar
  5. 5.
    Banerjee SS, Verma S, Shanks JH (2004) Morphological variants of plasma cell tumours. Histopathology 44:2–8CrossRefGoogle Scholar
  6. 6.
    Manasa Ravath CJ, Kulkarni N, Vinod R (2017) Mott cells—at a glance. Int J Contemp Med Res 4(1):43–44Google Scholar
  7. 7.
    Kumar K, Ningombam A, Irshad M, Parshuram PP (2018) Mott cells in peripheral blood smear of dengue fever (Haematocon 2018-596). Indian J Hematol Blood Transfus (issue 1 supplement):226Google Scholar
  8. 8.
    Dhiman P, Goel S, Samal P, Sood N, Sachdev R, Yadav SP, Vaid AK (2016) FISH analysis in multiple myeloma—a retrospective study from India. Blood 128(22):5646Google Scholar
  9. 9.
    Janet NB, Devasia AJ, Palle A, Maniapadam MT et al (2018) Multiple myeloma risk stratification by FISH analysis—a single centre experience. (Haematocon 2018-518). Indian J Hematol Blood Transfus 34(issue 1 supplement):374Google Scholar
  10. 10.
    Szabo AG, Gang AO, Poulsen TS, Klausen TW, Nørgaard PH (2012) T(11;14), cyclin D1, CD20 and CD56 in multiple myeloma: a retrospective study of pathologic and clinical associations. Blood 120:4983Google Scholar
  11. 11.
    Robillard N, Avet-Loiseau H, Garand R, Moreau P, Pineau D, Rapp MJ et al (2003) CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 102(3):10701CrossRefGoogle Scholar
  12. 12.
    Khan SHA, Mahesh K, Varghese RG (2018) Expression of Cd 20 and cyclin D1 in bone marrow biopsy of patients with multiple myeloma and its correlation with morphological features. (Haematocon 2018-180). Indian J Hematol Blood Transfus 34(issue 1 supplement):361Google Scholar
  13. 13.
    Hallgrimsdottir T, Porwit A, Björkholm M, Rossmann E, Steingrimsdottir H, Lund SH, Kristinsson SY (1946) Bone marrow fibrosis in patients with multiple myeloma: a new prognostic factor for survival? Blood 2013:122Google Scholar
  14. 14.
    Murthy P, Mahajan S, Singh T (2018) Bone marrow fibrosis in multiple myeloma. (Haematocon 2018-367). Indian J Hematol Blood Transfus 34(supplement):370Google Scholar
  15. 15.
    Coppola A, Tufano A, Di Capua M, Franchini M (2011) Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost 37(8):929–945CrossRefGoogle Scholar
  16. 16.
    Purohit A, Bohra GK, Bohra HK, Ahari K (2018) Multiple myeloma presenting as bleeding diathesis—an atypical presentation. (Haematocon 2018-321). Indian J Hematol Blood Transfus 34(supplement):367Google Scholar
  17. 17.
    Heinz Ludwig P et al (2008) Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood 111:4039CrossRefGoogle Scholar
  18. 18.
    Rumi MSIS, Chowdhury S, Jahan D, Muquit T, Saleh A (2018) A-29-year young male patient with multiple myeloma. (Haematocon 2018-392). Indian J Hematol Blood Transfus 34(supplement):371Google Scholar
  19. 19.
    Dimopoulos MA, Sonneveld P, Leung N et al (2016) International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 34(13):1544–1557CrossRefGoogle Scholar
  20. 20.
    Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C, On Behalf of the ESMO Guidelines Committee (2017) Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv52–iv61CrossRefGoogle Scholar
  21. 21.
    Terpos E, Kleber M, Engelhardt M et al (2015) European myeloma network guidelines for the management of multiple myeloma-related complications. Haematologica 100:1254–1266CrossRefGoogle Scholar
  22. 22.
    Dimopoulos MA, Terpos E, Chanan-Khan A et al (2010) Renal impairment in patients with multiple myeloma: a consensus statement on behalf the International Myeloma Working Group. J Clin Oncol 28:4976–4984CrossRefGoogle Scholar
  23. 23.
    Nath UK, Chetia R. Renal salvage with bortezomib/cyclophosphamide/dexamethasone therapy in newly diagnosed multiple myeloma patients with renal insufficiency: a single-center study. (Haematocon 2018-396). Indian J Hematol Blood Transfus 34(supplement):60Google Scholar
  24. 24.
    Rajkumar SV, Kumar S (2016) Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 91(1):101–119CrossRefGoogle Scholar
  25. 25.
    Cavo M, Pantani L, Pezzi A, Petrucci MT, Patriarca F, Di Raimondo F, Marzocchi G, Galli M, Montefusco V, Zamagni E, Gamberi B, Tacchetti P, Brioli A, Palumbo A, Sonneveld P (2015) Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Leukemia 29:2429–2431CrossRefGoogle Scholar
  26. 26.
    Kumar NM, Kalita PP, Bhattacharya J, Dutta S, Talukdar A, Barman R (2018) Study on prognostic factors and short term outcome of treatment of multiple myeloma patients at a tertiary care hospital. (Haematocon 2018-363). Indian J Hematol Blood Transfus 34(supplement):369Google Scholar
  27. 27.
    Jitani AK, Dolai TK, Mandal PK, Baul SN et al (2018) Bortezomib-thalidomide-dexamethasone (Vtd) in newly diagnosed multiple myeloma: a real world experience. (Haematocon 2018-242). Indian J Hematol Blood Transfus 34(supplement):364Google Scholar
  28. 28.
    Uysal A, Akad Soyer N, Özkan M, Şahin F, Vural F, Töbü M, Tombuloğlu M, Saydam G (2018) Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience. Turk J Med Sci 48(1):80–83CrossRefGoogle Scholar
  29. 29.
    Demopoulos MA, Goldschmidt H, Niesvizky R et al (2017) Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 18:1327–1337CrossRefGoogle Scholar
  30. 30.
    Sandal R, Jandial A, Mishra K, Lad D et al (2018) Real world experience of generic carfilzomib for relapsed refractory multiple myeloma (Rrmm). (Haematocon 2018-515). Indian J Hematol Blood Transfus 34(supplement):372Google Scholar
  31. 31.
    Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L et al (2018) From transplant to novel cellular therapies in multiple myeloma: European myeloma network guidelines and future perspectives. Haematologica 103(2):197–211CrossRefGoogle Scholar
  32. 32.
    Uday Y, Yadav S, Das SR, Kapoor R et al (2018) Multiple myeloma- real world experience of transplantation in multiple myeloma from a tertiary care centre in North India. (Haematocon 2018-573). Indian J Hematol Blood Transfus 34(supplement):61Google Scholar
  33. 33.
    Auner HW, Iacobelli S, Sbianchi G, Knol-Bout C et al (2018) Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the collaboration to collect autologous transplant outcomes in lymphoma and myeloma (CALM) study. A report by the EBMT chronic malignancies working party. Haematologica 103(3):514–521CrossRefGoogle Scholar
  34. 34.
    Kardduss-Urueta A, Gale RP, Gutierrez-Aguirre CH, Herrera-Rojas MA, Murrieta-Álvarez I, PerezFontalvo R, Ruiz-Delgado GJ, Ruiz-Rojas G, Jaimovich G, Feldman L, Labastida-Mercado N, Endara A, Castro M, Galindo-Becerra S, Cardona-Molina MA, Gomez-Almaguer D, Ruiz-Argüelles GJ (2018) Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas. Bone Marrow Transplant 53:457–460CrossRefGoogle Scholar
  35. 35.
    Kulkarni U, Devasia AJ, Korula A, Fouzia NA et al (2018) Use of non-cryopreserved peripheral blood stem cells is associated with adequate engraftment in patients with multiple myeloma undergoing an autologous transplant. (Haematocon 2018-522). Indian J Hematol Blood Transfus 34(supplement):63Google Scholar
  36. 36.
    Raghavan V, Nair CK, Avaronnan M, Shenoy PK et al (2018) Unmet needs in multiple myeloma patients: experience from a tertiary cancer centre in South India. (Haematocon 2018-532). Indian J Hematol Blood Transfus 34(supplement):375Google Scholar
  37. 37.
    Avaronnan M, Raghavan V, Shenoy PK, Sanjeev Kumar PB et al (2018) Health related quality of life in patients with multiple myeloma on novel agents: experience from a tertiary cancer centre in south India. (Haematocon 2018-568). Indian J Hematol Blood Transfus 34(supplement):376Google Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2019

Authors and Affiliations

  1. 1.Department of Lab Medicine and Molecular MedicineAH (R&R)New DelhiIndia

Personalised recommendations